Next Article in Journal
The Impact of Synaptic Zn2+ Dynamics on Cognition and Its Decline
Next Article in Special Issue
Immunotherapy for Prostate Cancer: Where We Are Headed
Previous Article in Journal
Environmental Burkholderia cenocepacia Strain Enhances Fitness by Serial Passages during Long-Term Chronic Airways Infection in Mice
Previous Article in Special Issue
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(11), 2413;

Targeting Immune Cell Checkpoints during Sepsis

Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
Author to whom correspondence should be addressed.
Received: 18 October 2017 / Revised: 10 November 2017 / Accepted: 12 November 2017 / Published: 14 November 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
PDF [1174 KB, uploaded 14 November 2017]


Immunosuppression is increasingly being recognized as one of the causes of increased morbidity and mortality during sepsis. Both innate and adaptive immune system dysfunction have been shown to cause an impaired ability to eradicate the primary infection and also lead to frequent occurrence of secondary opportunistic infections. Pre-clinical and clinical studies have shown that inhibitory immune checkpoint molecules, including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), T cell membrane protein-3 (TIM-3), Lymphocyte activation-gene-3 (LAG-3) and 2B4, are upregulated during the course of sepsis. Engagement of these inhibitory molecules on various immune cells has been consistently shown to inhibit innate immune cell functions (e.g., phagocytosis, cytokine production and pathogen clearance) and also lead to impaired T cell competence. In numerous pre-clinical models of sepsis, therapeutic agents aimed at blocking engagement of inhibitory immune checkpoints on immune cells have been shown to improve innate and adaptive immune cell functions, increase host resistance to infection and significantly improve survival. Therefore, immunotherapy with immune cell checkpoint inhibitors holds significant potential for the future of sepsis therapy and merits further investigation. View Full-Text
Keywords: sepsis; immunotherapy; T cell exhaustion; PD-1; PD-L1; CTLA-4; BTLA; TIM-3; LAG-3; 2B4; myeloid cells; immunosuppression sepsis; immunotherapy; T cell exhaustion; PD-1; PD-L1; CTLA-4; BTLA; TIM-3; LAG-3; 2B4; myeloid cells; immunosuppression

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Patil, N.K.; Guo, Y.; Luan, L.; Sherwood, E.R. Targeting Immune Cell Checkpoints during Sepsis. Int. J. Mol. Sci. 2017, 18, 2413.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top